Biotinylated HLA-A*011:01 KRAS G12V peptide complex

//Biotinylated HLA-A*011:01 KRAS G12V peptide complex

Biotinylated HLA-A*011:01 KRAS G12V peptide complex



accession KRAS

Source DNA sequence encoding the Human (HLA-A*011:01) AA25-305 [accession# P04439] and the B2M protein AA2-119 [accession# P61769], fused to the mutant G12V KRAS epitope VVVGADGVGK .This complex includes a C terminal polyHis and was expressed in HEK cells, This protein was then biotinylated site specific using the AVItag biotinylation technology
Molecular weight Recombinant HLA-A/KRAS G12V has a calculated mass of approximately 50kDa. Due to glycosylation migrates as an approximately 60 kDa protein under reducing conditions in SDS-PAGE.
Purity purity was determined to be >95% by nonreducing PAGE and HPLC (see below methods)
Endotoxin Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
Presentation Recombinant HLA-A*011:01 KRAS G12V complex was lyophilized from 0.2 µm filtered PBS solution pH7.4
Reconstitution A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Storage The lyophilized protein is stable for at least 2 years from date of receipt at -20° C.
Usage This product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.


Biotinylated KRAS G12V (HLA-A*11:01) HPLC

  • The purity of KRAS G12V (HLA-A*11:01)complex was greater than 95% as determined by SEC-HPLC.

Biotinylated KRAS G12D (HLA-A*11:01)protein PAGE

  • 1ug loaded Tris-Bis PAGE under reducing condition. The purity is greater than 95%.